EUVIMEDOpdag EUVIMED
Crossref

Biomimetic Ginsenoside Rb1 and Probucol Co-Assembled Nanoparticles for Targeted Atherosclerosis Therapy via Inhibition of Oxidative Stress, Inflammation, and Lipid Deposition

Jieying Zeng, Yuxin Zhang, Yan Gao, Mengjie Jia, Yajie Guo, Xinting Li, Yufan Wang, Chuanrong Zhao, Juhui Qiu, Sean McGinty, Wenjun Miao, Guixue Wang iD and 1 more

ACS Nano · 2025-07-01 · 19 (25) · 22968-22987

DOI: 10.1021/acsnano.5c02492 ↗

At a glance

Journal article in ACS Nano, published online on 2025-06-19. Written by Jieying Zeng and 12 co-authors. Institution: School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China. Major MEDLINE topics: Ginsenosides, Atherosclerosis, Probucol, Nanoparticles. Cited 96 times so far (Crossref); 56 references. Funded by: Natural Science Foundation of Chongqing Municipality, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

To overcome the limitations of conventional oral drugs and nanocarrier-dependent delivery systems in atherosclerosis (AS) therapy, our work proposes an "integration of Chinese and Western medicine" approach to develop a new biomimetic traditional Chinese and Western medicine components coassembled nanoparticles (NPs), termed as MMVs/RPNPs, for targeted AS therapy. In this work, we demonstrated that ginsenoside Rb1 can coassemble with probucol without excipients to form stable carrier-free NPs, termed RPNPs. To impart the specific targeting property to atherosclerotic sites, macrophage microvesicles (MMVs) were utilized to coat the RPNPs to obtain the MMVs/RPNPs. Developed MMVs/RPNPs exhibited excellent capabilities in eliminating intracellular ROS, suppressing pro-inflammatory factor secretion, and inhibiting intracellular lipid deposition in vitro. In a mouse model of AS, MMVs/RPNPs efficiently accumulated at atherosclerotic sites following intravenous injection and effectively retarded atherosclerotic plaque formation through synergistic effects of antioxidative stress, anti-inflammation, and inhibition of lipid deposition. Additionally, MMVs/RPNPs did not cause any adverse effects with long-term treatment. Our work presents simple, effective, and safe NPs against AS and underscores the potential of the "integration of Chinese and Western medicine" strategy for treating other cardio-cerebrovascular diseases.

Subjects

MeSH terms (MEDLINE)

GinsenosidesAtherosclerosisProbucolNanoparticlesOxidative StressInflammationBiomimetic MaterialsAnimalsMiceHumansMice, Inbred C57BLMaleRAW 264.7 CellsMacrophagesLipid MetabolismAnti-Inflammatory Agents

Author keywords

atherosclerosisbiomimeticcarrier-free coassembly nanoparticleslipid depositionoxidative stress and inflammation

Substances

GinsenosidesProbucolginsenoside Rb1Anti-Inflammatory Agents

Authors and institutions

  • School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China.
  • Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
  • Key Laboratory for Biorheological Science and Technology of the Ministry of Education, National Local Joint Engineering Lab for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400044, China.
  • Division of Biomedical Engineering, University of Glasgow, Glasgow G12 8QQ, U.K.
  • JinFeng Laboratory, Chongqing 401329, China.

ORCID profiles: Guixue Wang

Funding

  • Natural Science Foundation of Chongqing Municipality
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Science and Technology Innovation Project of Jinfeng Laboratory
  • Chongqing Traditional Chinese Medicine Innovation Team Construction Project

Cite

APA

Zeng, J., Zhang, Y., Gao, Y., Jia, M., Guo, Y., Li, X., Wang, Y., Zhao, C., Qiu, J., McGinty, S., Miao, W., Wang, G., & Wang, Y. (2025). Biomimetic Ginsenoside Rb1 and Probucol Co-Assembled Nanoparticles for Targeted Atherosclerosis Therapy via Inhibition of Oxidative Stress, Inflammation, and Lipid Deposition. ACS Nano, 19(25), 22968-22987. https://doi.org/10.1021/acsnano.5c02492

Vancouver

Zeng J, Zhang Y, Gao Y, Jia M, Guo Y, Li X, et al. Biomimetic Ginsenoside Rb1 and Probucol Co-Assembled Nanoparticles for Targeted Atherosclerosis Therapy via Inhibition of Oxidative Stress, Inflammation, and Lipid Deposition. ACS Nano. 2025;19(25):22968-22987. doi:10.1021/acsnano.5c02492

BibTeX
@article{Zeng2025,
  author = {Zeng, Jieying and Zhang, Yuxin and Gao, Yan and Jia, Mengjie and Guo, Yajie and Li, Xinting and Wang, Yufan and Zhao, Chuanrong and Qiu, Juhui and McGinty, Sean and Miao, Wenjun and Wang, Guixue and Wang, Yi},
  title = {Biomimetic Ginsenoside Rb1 and Probucol Co-Assembled Nanoparticles for Targeted Atherosclerosis Therapy via Inhibition of Oxidative Stress, Inflammation, and Lipid Deposition},
  journal = {ACS Nano},
  year = {2025},
  volume = {19},
  number = {25},
  pages = {22968--22987},
  doi = {10.1021/acsnano.5c02492}
}
Start for free →